

Lumos Diagnostics Holdings Limited
Appendix 4E
Preliminary final report

1. Company details

Name of entity:	Lumos Diagnostics Holdings Limited
ABN:	66 630 476 970
Reporting period:	For the year ended 30 June 2025
Previous period:	For the year ended 30 June 2024

2. Results for announcement to the market

US\$'000			
Revenues from ordinary activities	up	11.4% to	12,400
Loss from ordinary activities after tax attributable to the owners of Lumos Diagnostics Holdings Limited	down	16.4% to	(7,183)
Loss for the year attributable to the owners of Lumos Diagnostics Holdings Limited	down	16.4% to	(7,183)

Comments

The loss for the consolidated entity after providing for income tax amounted to US\$7,183 thousand (30 June 2024: loss of US\$8,592 thousand).

3. Net tangible assets

	Reporting period US\$ Cents	Previous period US\$ Cents
Net tangible assets per ordinary security	(0.14)	(0.37)

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable. All foreign entities have adopted the same accounting standards as the Australian parent entity.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unmodified opinion has been issued, which includes a paragraph in respect of material uncertainty over the ability to continue as a going concern.

11. Attachments

Details of attachments (if any):

The Annual Report of Lumos Diagnostics Holdings Limited for the year ended 30 June 2025 is attached.

12. Signed

Signed



Samuel Lanyon
Non-Executive Chair

Date: 28 August 2025